TriSalus Life Sciences's gross profit for the
three
months ended in Mar. 2024 was $5.49 Mil. TriSalus Life Sciences's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $19.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TriSalus Life Sciences's Gross Profit
For the Medical Devices subindustry, TriSalus Life Sciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Gross Profit falls into.
TriSalus Life Sciences Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
TriSalus Life Sciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.07 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
TriSalus Life Sciences (NAS:TLSI) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
TriSalus Life Sciences had a gross margin of 84.96% for the quarter that ended in Mar. 2024 => Durable competitive advantage
TriSalus Life Sciences Gross Profit Related Terms
Thank you for viewing the detailed overview of TriSalus Life Sciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
TriSalus Life Sciences (TriSalus Life Sciences) Business Description
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TLSI has been successfully added to your 